Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay M Edelberg

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Circulation|March 9, 2005
Cytokine preconditioning promotes codifferentiation of human fetal liver CD133+ stem cells into angiomyogenic tissueSergey V Shmelkov, Sarah Meeus, Nelson Moussazadeh, et al.
Journal of the American College of Cardiology|July 7, 2022
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction TherapyMilind Y Desai, Anjali Owens, Jeffrey B Geske, et al.
Journal of the American College of Cardiology|April 8, 2026
Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical TrialLuke J Laffin, Qiuqing Wang, Ashish Sarraju, et al.
JACC. Advances|December 11, 2023
Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker CorrelationsKonstantinos C Siontis, Sean Abreau, Zachi I Attia, et al.
European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.
Journal of the American College of Cardiology|March 23, 2019
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES TrialJ Wouter Jukema, Michael Szarek, Laurien E Zijlstra, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology|August 31, 2019
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass SurgeryShaun G Goodman, Philip E Aylward, Michael Szarek, et al.
The New England Journal of Medicine|November 8, 2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G Schwartz, P Gabriel Steg, Michael Szarek, et al.
Circulation|May 24, 2019
Effect of Alirocumab on Mortality After Acute Coronary SyndromesPhilippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Circulation|March 9, 2005
Cytokine preconditioning promotes codifferentiation of human fetal liver CD133+ stem cells into angiomyogenic tissueSergey V Shmelkov, Sarah Meeus, Nelson Moussazadeh, et al.
Journal of the American College of Cardiology|July 7, 2022
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction TherapyMilind Y Desai, Anjali Owens, Jeffrey B Geske, et al.
Journal of the American College of Cardiology|April 8, 2026
Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical TrialLuke J Laffin, Qiuqing Wang, Ashish Sarraju, et al.
JACC. Advances|December 11, 2023
Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker CorrelationsKonstantinos C Siontis, Sean Abreau, Zachi I Attia, et al.
European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.
Journal of the American College of Cardiology|March 23, 2019
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES TrialJ Wouter Jukema, Michael Szarek, Laurien E Zijlstra, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology|August 31, 2019
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass SurgeryShaun G Goodman, Philip E Aylward, Michael Szarek, et al.
The New England Journal of Medicine|November 8, 2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G Schwartz, P Gabriel Steg, Michael Szarek, et al.
Circulation|May 24, 2019
Effect of Alirocumab on Mortality After Acute Coronary SyndromesPhilippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, et al.
Pageof 6